August 1, 2006 -- Nuvelo expanded its CV collaboration with privately held Archemix, splitting duties and giving Archemix an upfront payment; Enzon will begin a Phase I test of Oncaspar against cancer; Innovata and Baxter won FDA approval for ADEPT; MGI Pharma received orphan designation in Europe for Dacogen; Ono Pharma and Medarex asked for an FDA OK to begin clinical trials of a cancer drug; Critical Therapeutics filed a New Drug Application for a long-acting formulation of its asthma drug, Zyflo; Hemispherx bought the royalty interest to Alferon N Injection; Oscient Pharma won approval for Factive-5 in Mexico;Takeda Pharma and BioNumerik said Tavocept failed its Phase III trials; and CV Therapeutics pointed to a journal article showing its asthma drug reduced inflammation markers. The Centient Biotech 200™ closed with a 15 point loss at 3656.98, a drop of .41%. More details...
